Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication (ITD) in FLT3. Adults (aged 18–70 years) who received al...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Bone Marrow Transplant
Prif Awduron: Maziarz, Richard T., Levis, Mark, Patnaik, Mrinal M., Scott, Bart L., Mohan, Sanjay R., Deol, Abhinav, Rowley, Scott D., Kim, Dennis D. H., Hernandez, Daniela, Rajkhowa, Trivikram, Haines, Kelly, Bonifacio, Gaetano, Rine, Patrice, Purkayastha, Das, Fernandez, Hugo F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8113057/
https://ncbi.nlm.nih.gov/pubmed/33288862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41409-020-01153-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg